Topics covered in this edition of the newsleter include:
Strontium ranelate (Protelos) - New restricted indication and monitoring recommendations due to concerns regarding cardiovascular safety
Hydroxyethylstarch (HES) Infusion Solutions - EU review confirms they are not to be used in patients with sepsis or burn injuries or in critically ill patients
Cetuximab (Erbitux) - Update on revised recommendations for use and risk of infusion-related reactions
Direct Healthcare Professsional Communications published on the IMB website since the last Drug Safety Newsletter